Literature DB >> 19863472

Ovarian cancer screening and early detection.

Andrea B Joyner1, Carolyn D Runowicz.   

Abstract

One of the most challenging issues in gynecologic oncology is the high mortality rate of ovarian cancer, largely due to detection of disease in advanced stages. Women with early-stage disease have a significantly improved survival rate and may not require chemotherapy. Thus, the issues to examine are whether there are methods to improve early detection, thereby resulting in a reduction in mortality. Several large, randomized, clinical trials have recently completed evaluating CA 125 and transvaginal sonography as effective strategies to accomplish this goal. These issues and the results of the recent trials will be reviewed in this article.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19863472     DOI: 10.2217/whe.09.65

Source DB:  PubMed          Journal:  Womens Health (Lond)        ISSN: 1745-5057


  4 in total

1.  Combined use of biomarkers for detection of ovarian cancer in high-risk women.

Authors:  Martin Donach; Yinhua Yu; Grazia Artioli; Giuseppe Banna; Weiwei Feng; Robert C Bast; Zhen Zhang; Maria O Nicoletto
Journal:  Tumour Biol       Date:  2010-06

2.  Development and validation of a nomogram to predict overall survival of T1 esophageal squamous cell carcinoma patients with lymph node metastasis.

Authors:  Jia Yu; Wenyu Hu; Nan Yao; Mengzi Sun; Xiaotong Li; Ling Wang; Yixue Yang; Bo Li
Journal:  Transl Oncol       Date:  2021-05-18       Impact factor: 4.243

3.  Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer.

Authors:  Soozana Puvanenthiran; Sharadah Essapen; Ben Haagsma; Izhar Bagwan; Margaret Green; Said Abdullah Khelwatty; Alan Seddon; Helmout Modjtahedi
Journal:  Oncotarget       Date:  2018-04-13

4.  Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses.

Authors:  Heng Zheng; Yan Tie; Xi Wang; Yang Yang; Xiawei Wei; Xia Zhao
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.